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ABSTRACT 
 
 
OBJECTIVE:  The objective of this selective EBM review is to determine whether or not 
L-carnitine decreases mortality rates post MI. 
 
STUDY DESIGN: Review of three randomized controlled trials published in 1996, 2000, 
and 2012, all English language. 
 
DATA SOURCES: Three double blind, randomized controlled clinical trials comparing 
mortality rates in patients post MI who were treated with L-carnitine or a placebo. All 
articles were found using PubMed and EBSCO. 
 
OUTCOMES MEASURED:  
In the Singh et al. study the outcomes were total cardiac events that included death and 
nonfatal infarctions, cardiac enzymes activity, infarct size, and any complications that 
were measured by myocardial infarct size, cardiac enzyme levels of CK and CK-MB, 
radiology, and electrocardiographic. In the Colonna study, outcomes were:  left 
ventricular dilation, end diastolic volume, systolic volume, incidence of death and heart 
failure at 6 months, and infarct size that were measured by an echocardiograph.  In the 
Tarantini study, the outcomes measured were: combined occurrence of death and heart 
failure that were measured by deaths. 
 
RESULTS: In the Singh et al. study the total cardiac events including nonfatal infarction 
and cardiac deaths were significantly fewer in the L-carnitine group compared to placebo 
in 28 days. In the Tarantini study, a reduction in mortality was seen in the L-carnitine arm 
of the study at 5 days. The	  Colonna	  study	  results	  shows	  L-­‐Carnitine	  does	  not	  seem	  to	  be	  effective	  in	  reducing	  mortality	  in	  patients	  after	  AMI. 
 
CONCLUSIONS:  The results of these RCTs suggest that L-carnitine isn’t much more 
effective in reducing mortality rates after AMIs than the placebo. There	  was	  some	  evidence	  to	  suggest	  that	  L-­‐carnitine	  may	  be	  effective	  in	  reducing	  mortality	  short-­‐term	  after	  an	  AMI	  but	  not	  long	  term.	  	  	  The	  studies	  reviewed	  demonstrated	  statistically	  significant	  decreases	  in	  mortality	  only	  in	  the	  time	  frame	  directly	  following	  an	  AMI.	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INTRODUCTION 
 Myocardial infarction (MI or heart attack) occurs when blood flow is blocked to an area 
of the heart muscle that causes ischemic damage or death to the myocardial cells. Myocardial 
infarctions are potentially fatal conditions that are among the leading causes of death in both men 
and women worldwide. Carnitine plays a critical role in energy production and is found in high 
concentrations in cardiac muscle1. This paper evaluates three randomized controlled trials 
(RCTs) comparing the efficacy of L-Carnitine in preventing mortality in patients post myocardial 
infarction.  
 This topic/question is relevant to patients, doctors, and physician assistant practice 
because it is common, costly and accounts for a significant amount of healthcare visits.  
Prevalence of myocardial infarctions increase with age.  It is estimated that 60-65% of MIs occur 
in patients above 65 years old and 28-33% occur in patients above 75 years old. Eighty percent 
of all deaths related to myocardial infarctions occur in persons above 65 years of age2. Coronary 
heart diseases cost $108.9 billion each year in the US3.  Coronary heart disease and myocardial 
infarctions account for a significant amount of healthcare visits: in 2010, AHA reports that 17.6 
million people in the United States have coronary heart disease with 8.5 million having 
myocardial infarctions4. 
 Myocardial infarction is defined as a clinical (or pathologic) event caused by myocardial 
ischemia in which there is evidence of myocardial injury or necrosis. Detection of a rise and fall 
of cardiac biomarker values is a crucial criterion in the diagnosis of MIs. Additionally, at least 
one of the following criteria are also needed to verify the diagnosis: symptoms of ischemia, 
development of pathologic Q waves in the electrocardiography (ECG), new or presumed new 
significant ST segment-T wave changes or new left bundle branch block (LBBB), identification 
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of an intracoronary thrombus by angiography or autopsy, imaging evidence of new loss or viable 
myocardium or a new regional wall motion abnormality4. 
 The usual methods of treatments of myocardial infarction and coronary artery disease are:  
relief of ischemic pain and oxygen therapy, assessment of the hemodynamic state and correction 
of abnormalities, initiation of reperfusion therapy with primary PCI or fibrinolysis, 
antithrombotic therapy to prevent re-thrombosis or acute stent thrombosis, beta blocker therapy 
to prevent recurrent ischemia and arrhythmias, Coronary Artery Bypass Graft (CABG), and 
lifestyle modifications: diet, EtOH, smoking cessation, and weight loss2. 
 Carnitine is found in high concentrations in cardiac muscle and serves several important 
physiological functions in the heart5. This method of treatment is being proposed to determine if 
L-carnitine decreases infarct sizes because carnitine deficiency is more significant in the 
infarcted portion of the myocardium than in healthy myocardium. Studies have shown 
potentially beneficial effects with L-carnitine administration in improving clinical status and 
survival of patients post myocardial infarctions4. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not L-carnitine 
decreases mortality rates post myocardial infarction. 
METHODS 
 The RCTs analyzed patients who had an acute myocardial infarction within 8-10 hours of 
symptoms. The intervention studied in the RCTs was L-Carnitine. In the Singh et al. study, 
patients were given 1.98g/d of L-Carintine6. In the Colonna et al. study, patients were given L-
Carnitine 9g/d continuous IV for the first 5 days, then PO 2g TID for next 12 months7.  In the 
Tarantini et al. study, patients were given L-carnitine 9g/d by continuous IV infusion for initial 5 
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days then 4g/d orally for next 6 months8.  In all three RCTs, treatment groups received L-
Carnitine compared to the experimental group who received a placebo at the same dosage 
schedules. The following are measured outcomes that were utilized:  total cardiac events 
including death and nonfatal infarctions, cardiac enzymes activity, infarct size, and 
complications (heart failure, and left ventricular dilation). 
 Key words used in the searches were “L-Carnitine” and “Myocardial Infarction”. All 
articles were published in peer-reviewed journals in the English language. The articles were 
selected through PubMed and EBSCO; the selected articles were based on relevance to the 
clinical question and that the studies outcomes were patient oriented outcomes (POEMs). 
Inclusion criteria consisted of: patients who were judged to likely have an acute myocardial 
infarction with onset of symptoms in the preceding 12-24 hours. Patients had either persistent ST 
elevation of 0.2 mV or more in two or more contiguous precordial leads, elevated cardiac 
enzymes, and continuous typical chest pain for at least 30 minutes unrelieved by sublingual or IV 
nitrates. Exclusion criteria consisted of studies previous acute MI, valvular or congenital heart 
disease, cardiomyopathy, absence of sinus rhythm, LBBB, pregnant, severe comorbidities, 
greater than 80 years of age, and patients unwilling or unable to give consent. The summary of 
statistics reported or used were p values, RBI, ABI, and NNT. 
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Table 1:  Demographics and Characteristics of included studies 
Study Type # Pts Age 
(yrs) 
Inclusion 
criteria 
Exclusion 
criteria 
W/D Interventi
on 
Singh6 
(1996) 
Randomized, 
double-
blind, 
placebo 
controlled 
trial 
101 Avg 
40-
50s 
y/o 
Judge likely to 
have AMI 
with onset of 
sxs in the 
preceding 24 
hrs 
Patients unable 
or unwilling to 
give consent, 
Admitted more 
than 24 hrs after 
onset of sxs 
 
0 oral L-
Carnitine 
1.98g/d 
Colonna7 
(2000) 
Multicenter, 
randomized, 
double-blind 
trial 
472 < 80 
y/o 
Seen at an 
ICU within 24 
h of having 
their first 
acute anterior 
MI 
Previous acute 
MI, Valvular or 
congenital heart 
disease, 
Cardiomyopathy, 
Absence of sinus 
rhythm, Left 
bundle branch 
block, Pregnant, 
Concomitant 
conditions that 
could affect 
follow-up, and 
Participating in 
another clinical 
study 
 Carnitine 
9g/d 
continuou
s IV for 
the first 5 
days, then 
PO 2g 
TID for 
next 12 
months 
Tarantini8 
(2012) 
Randomized, 
double-
blind, 
placebo 
controlled 
trial 
2,330 < 80 
y/o 
Continuous 
typical CP for 
at least 30 min 
unrelieved by 
s.l. or IV 
nitrates, Onset 
of sxs of AMI 
within 12 h 
before 
randomization, 
and Persistent 
ST elevation 
of 0.2 mV or 
more in two or 
more 
contiguous 
precordial 
leads 
 
Age >80 y/o, 
Valvular or 
congenital heart 
disease, HCM, 
Severe renal or 
hepatic disorder, 
comorbidity 
limiting the pt’s 
life expectancy, 
Alcoholism, 
Pregnancy or 
lactation, and 
Unwillingness to 
provide informed 
consent 
 
1 L-
carnitine 
9g/d by 
continuou
s IV 
infusion 
for initial 
5 days 
then 4g/d 
orally for 
next 6 
months 
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OUTCOMES MEASURED 
 Outcomes measured in the Singh et al. study were:  total cardiac events including death 
and nonfatal infarctions, cardiac enzymes activity, infarct size, and complication were measured 
by myocardial infarct size, levels of CK and CK-MB, electrocardiographic, complications at 28 
days follow up that included deaths, LV function, arrhythmia, nonfatal re-infarction, and total 
cardiac events.6 The Colonna et al. RCT study measured outcomes such as left ventricular 
dilation, end diastolic volume, systolic volume, incidence of death of heart failure at 6 months, 
infarct size, and residual stenosis that was measured by an Echocardiograph.7 The outcomes 
measured by Tarantini et al. RCT study outcomes were combined occurrence of death and heart 
failure that was measured by number of deaths at various times from randomization.8 
RESULTS 
 The three randomized-controlled trials compared the efficacy of L-Carnitine to placebo in 
preventing mortality in patients post myocardial infarction.  
 In the study by Singh et al, total cardiac events, which were defined as cardiac deaths and 
nonfatal re-infarctions, were 15.6% in the L-carnitine group and 26.0% in the placebo group. 
There was no significant decrease in cardiac deaths with treatment with L-carnitine vs. placebo 
with p>0.05 and Confidence Limits (CL) (1.88, 0.22). There was a significant decrease in 
nonfatal re-infarctions with L-carnitine vs placebo with p<0.05, Confidence Limits (CL) (1.86, 
0.17). There was also a significant decrease in total cardiac events with L-carnitine vs placebo 
with p<0.05 and Confidence Limits (CL) (1.62, 0.27). The treatment effects of L-carnitine on 
mortality post MI are listed in Table 2.  The relative risk reduction (RRR) is -0.4% and the 
absolute risk reduction (ARR) is -10.4%. The numbers needed to treat (NNT) was -9. All data 
Spearman, L-Carnitine reduce death post MI  	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were analyzed on the basis of intention to treat and the outcome analyses were incorporated for 
patients who were lost to follow up or died6. 
Table 2: Treatment effects of L-carnitine treatment post AMI on cardiac events 
CER EER RRR ARR NNT 
0.26 0.156 -0.4 -0.104 -9 
 
 In the study by Taratini et al, at 6 months post MI the survival rate was not significantly 
increased for L-carnitine group vs placebo group as determined by p=0.48.  But at day 5 post MI, 
the survival rate was significantly higher for the L-carnitine group vs placebo group with 
p=0.041. The cumulative mortality rate at various times are as follows: at 0-5 days the 
confidence interval (CI) was 0.37- 0.98 and p-value < 0.05; at 0-7 days the CI was 0.42- 1.05 and 
p-value > 0.05; at 0-15 days the CI was 0.54- 1.26 and p-value > 0.05; at 0-30 days the CI was 
0.53- 1.16 and p-value > 0.05; at 0-60 days the CI was 0.56- 1.18 and p-value > 0.05; at 0-90 
days the CI was 0.60- 1.22 and p-value > 0.05; and at 0-180 days the CI was 0.63- 1.24 and p-
value > 0.05.  The treatment effects of L-carnitine on mortality are listed in table 3.  The relative 
risk reduction (RRR) is -0.12% and absolute risk reduction (ARR) is -1.3%. The number needed 
to treat (NNT) was -76.  At 6 months, total of 142 patients out of 2,330 patients died. There were 
67 patients that died the from the L-carnitine group which was a six-month mortality rate of 
5.7% and the mortality rate of the placebo group was 6.5% at six-months that lead to a non-
significant 12% reduction in mortality between L-carnitine and placebo (p=0.48).  The 
significant decreases in mortality were in the earlier periods of the study. At the five-day end 
point, the mortality reduction was significant in the L-carnitine group of CI 0.37 and p-value= 
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0.041. One patient assigned to the placebo group was loss to follow up and therefore was 
excluded from all analyses and “worst-case” analysis was not done to those lost to follow up8.  
Table 3: Reduction in mortality after MI with treatment with L-carnitine  
CER EER RRR ARR NNT P-value 
0.105 0.09.2 -0.12 -0.013 -76 0.041 
 
 The study by Colonna et al, measures death rates between patients treated with L-
carnitine vs. placebo during hospitalization and from discharge to 1 year follow up. During 
hospitalization 11 (4.7%) patients treated with L-carnitine died compared to 14 (5.9%) patients 
treated with the placebo. Between discharge and 1 year follow up, 10 (4.3%) patients treated 
with L-carnitine died compared to the placebo group where 13 (5.4%) patients died.  The 
treatment effects of L-carnitine on mortality reduction are listed in Table 4. The relative risk 
reduction (RRR) is -0.2% and the absolute risk reduction (ARR) is -2.3%. The number needed to 
treat (NNT) was -43. None of the participants in the study needed to discontinue the treatment. 
“Worst-case” analysis was not done to those lost to follow up7.  
Table 4: Mortality reduction post MI with treatment with L-carnitine  
CER EER RRR ARR NNT 
0.113 0.09 -0.2% -0.023 -43 
 
 None of the participants were reported to have adverse events in the reviewed studies 
from treatment with L-carnitine. 
DISCUSSION 
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 This selective evidence based medicine review investigated three randomized controlled 
trials to determine whether or not L-carnitine decreases mortality rates post myocardial 
infarction. While the selected studies provided no definitive evidence that L-carnitine decreased 
long-term mortality rates post myocardial infarction but these studies did suggest that L-carnitine 
might be helpful with infarction size and early mortality rates. 
 In the Singh study et al, total cardiac mortality rates did not show a significant reduction 
in the L-carnitine group compared to the placebo group (p>0.05) but did show a significant 
reduction in cardiac events, which were defined as cardiac deaths and nonfatal re-infarctions. For 
nonfatal re-infarctions with L-carnitine vs. placebo, there was a statistically significant decrease 
(p<0.05).  There was also a significant reduction in total cardiac events with L-carnitine 
treatment, (p<0.05). The relative risk reduction (RRR) was -0.4%, so there was a 0.4% decrease 
in adverse events with L-carnitine versus placebo.  The absolute risk reduction (ARR) is -10.4%, 
so there was a 10.4% decrease in adverse events with L-carnitine versus nothing.  These values 
are small and further demonstrate that L-carnitine is not much more effective than the placebo in 
reducing mortality after an AMI.  The authors of the article stated that carnitine may inhibit free 
radical injury to the myocardium, so this can be protective for the myocardium and non-infarcted 
areas. The study also suggests that there was a significant reduction in cardiac enzymes like 
creatine kinase, creatine kinase-MB, and aspartate transaminase and a smaller increase in lactate 
dehydrogenase, indicating less cardiac necrosis in the L-carnitine group. Decreasing necrotic 
areas of myocardium is a major goal of treating AMI. Current methods (nitro, oxygen therapy, 
CABG, stent) of trying to restore oxygenated blood flow are currently the gold standard but more 
studies should be done to further evaluate the usefulness of L-carnitine. Limitations of the study 
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may have been the samples size, comorbidities of the patients, and time sensitive drug therapy 
after onset of MI could have impacted the outcome 6 
 In the study by Colonna et al, there seems to be minimal benefit to using L-carnitine.  
The mortality rate during hospitalization was 4.7% when treated with L-carnitine compared to 
5.9% when treated with the placebo. Also, the mortality rates after discharge to one year follow 
up period were 4.3% for L-carnitine group compared to the placebo group at 5.4%. The RRR and 
ARR were both small showing that L-carnitine is not much more effective than the placebo in 
reducing mortality post MI.  The study suggests that long-term L-carnitine treatment limits left 
ventricular dilatation, which should help the patient to prevent future sequelae and even death 
from the AMI. Limitations to the study could have been different facilities MI protocols, 
patients’ comorbidities, and time sensitive drug therapy after onset of MI could have also 
impacted the outcomes7. 
 The study by Taratini et al, showed the mortality rate at 6 months was 5.7% for the L-
carnitine group and 6.5% for the placebo group. This was a non-significant, 12% reduction in 
long-term (baseline - 6 months) mortality (p=0.48) with L-carnitine vs. placebo.  However, the 
short-term (day 5) post MI survival rate was significant increased for the group treated with L-
carnitine group (p=0.041) as demonstrated by the cumulative mortality rate at 0-5 days.  But as 
stated in results portion, the cumulative mortality rate at 0-7 days, 0-15 days, 0-30 days, 0-60 
days, 0-90 days, and 0-180 days all showed p-value > 0.05 demonstrating a non-significant 
increase in those survival rates. RRR and ARR values were small and demonstrate that L-
carnitine is not much more effective than the placebo in reducing mortality after an AMI. The 
NNT was 76 people to have a positive outcome. Limitations of the study could have been 
comorbidities, and time sensitive drug therapy after onset of MI could have impacted the 
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outcome. Another limitation is the study was conducted at different facilities that may have 
different MI protocols. The study was terminated early due to the lower than expected 
enrollment rate so the samples size could have been another limitation8. 
 All three studies show some evidence of the usefulness of L-carnitine.  It does not 
necessary decrease long-term mortality rates because some MIs may cause too much damage for 
the individual patient to recover from the event.  Most medical professionals would agree 
decreasing infarcts sizes and cardiac enzymes, and preventing left ventricular dilatation will 
improve the chances of survival and quality of life for the patients post MI. It is common 
knowledge that “time is tissue” with cardiovascular events therefore, time to treatment and the 
size of the area of infarction may have a role in determining the treatment effects of L-carnitine. 
CONCLUSION 
 There is some evidence to suggest that L-carnitine may be effective in reducing mortality 
short-term after an AMI but not long term.   The studies reviewed demonstrated statistically 
significant decreases in mortality only in the time frame directly following an AMI.  Because of 
these results, future studies on the effects of L-carnitine should be conducted focusing on its 
efficacy short term after an AMI.  The flaws in the conducted studies may have been that they 
did not focus treatment on the short term, which is where L-carnitine appears to have the greatest 
treatment effect.  	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